Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Butyrate Formulation Clear all
Completed Phase 3 Interventional Results available

Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients

NCT01271933
View directory record Official record
Conditions
Fibromyalgia
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
30
States / cities
Orange, California • Santa Ana, California • Ocala, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 5, 2026, 10:50 PM EDT
Terminated Phase 3 Interventional Results available

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

NCT02626455
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 5, 2026, 10:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of a Butyrate Formulation and Butyrate + Polyphenol Formulation on Gut Health, Permeability and Associated Symptoms

NCT06419231
View directory record Official record
Conditions
Gut Health
Interventions
Butyrate Formulation, Butyrate + Polyphenol Formulation, Placebo
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 5, 2026, 10:50 PM EDT
Withdrawn Not applicable Interventional

Pendulum D2D Glucose Control for Adults With Type 2 Diabetes

NCT04228003
View directory record Official record
Conditions
Type2 Diabetes, Gastrointestinal Symptoms
Interventions
Pendulum Glucose Control formulation for T2D
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 5, 2026, 10:50 PM EDT
Recruiting Not applicable Interventional

Precision Medicine and Physical Function

NCT05877846
View directory record Official record
Conditions
Frailty, Weakness, Muscle, Multiple Chronic Conditions
Interventions
Beta-hydroxymethyl butyrate supplement, Vitamin D supplement, Matching Beta-hydroxymethyl butyrate supplement without Vitamin D
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 5, 2026, 10:50 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Butyrate Tablet BKR-017

NCT06556745
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
BKR-017
Drug
Lead sponsor
BioKier Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 5, 2026, 10:50 PM EDT
Completed Not applicable Interventional

Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients

NCT04673656
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
BKR-017
Dietary Supplement
Lead sponsor
BioKier Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Durham, North Carolina • Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 5, 2026, 10:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

NCT02257567
View directory record Official record
Conditions
Lymphoma
Interventions
Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid), Rituximab, Polatuzumab vedotin (Lyophilized)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Huntsville, Alabama • Duarte, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 5, 2026, 10:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted In The Evening or Immediately Following A 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers

NCT01321671
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin controlled release, 330 mg, 600- 750 calorie, Pregabalin controlled release, 330 mg, fasted, Pregabalin immediate release, 300 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 5, 2026, 10:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Baclofen for Children With Rumination Syndrome

NCT05975684
View directory record Official record
Conditions
Rumination Syndrome
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
4 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 5, 2026, 10:50 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers

NCT07611370
View directory record Official record
Conditions
Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Microencapsulated Sodium Butyrate, Microencapsulated Sodium Propionate
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 5, 2026, 10:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted At Bedtime Or Immediately Following A 400-500 or 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers

NCT01291524
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin controlled release, 330 mg, 400 to 500 calorie, Pregabalin controlled release, 330 mg, 600- 750 calorie, Pregabalin controlled release, 330 mg, bedtime, Pregabalin immediate release, 300 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 5, 2026, 10:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation

NCT01080612
View directory record Official record
Conditions
Healthy
Interventions
330 mg pregabalin controlled release, 300 mg pregabalin immediate release
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 5, 2026, 10:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers

NCT01257529
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin controlled release, 330 mg, low-fat, Pregabalin controlled release, 330 mg, medium-fat, Pregabalin controlled release, 330 mg, high-fat, Pregabalin immediate release, 300 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 5, 2026, 10:50 PM EDT
Completed Phase 1 Interventional

The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes

NCT02002130
View directory record Official record
Conditions
Type I Diabetes
Interventions
Placebo GABA and Placebo GAD-alum, GABA and Placebo GAD-alum, Active Oral GABA and Active GAD-alum injection
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
4 Years to 18 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Sep 5, 2026, 10:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of a Butyrate-Polyphenol Formulation on Gut Health and Associated Symptoms

NCT07371975
View directory record Official record
Conditions
Gut Health
Interventions
Butyrate + Polyphenol Formulation, Placebo
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
25 Years to 70 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 5, 2026, 10:50 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

NCT05451771
View directory record Official record
Conditions
AL Amyloidosis
Interventions
Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg, Dexamethasone Oral, 10 mg, Dexamethasone Oral, 20 mg, Daratumumab Injection, Bendamustine, Pomalidomide, Ixazomib, Venetoclax MTD with Dexamethasone
Drug · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 5, 2026, 10:50 PM EDT
Completed Phase 3 Interventional Results available

Once-A-Day Pregabalin For Partial Seizures

NCT01262677
View directory record Official record
Conditions
Partial Seizures, Epilepsies, Partial
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 5, 2026, 10:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following Various Sized Lunches As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers

NCT01270815
View directory record Official record
Conditions
Healthy
Interventions
Pregabalin controlled release, 330 mg, 400 to 500 calories, Pregabalin controlled release, 330 mg, 600 to 750 calories, Pregabalin controlled release, 330 mg, 800 to 1000 calories, Pregabalin immediate release, 300 mg
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 5, 2026, 10:50 PM EDT